Progressively impaired proteasomal capacity during terminal plasma cell differentiation

被引:137
作者
Cenci, S
Mezghrani, A
Cascio, P
Bianchi, G
Cerruti, F
Fra, A
Lelouard, H
Masciarelli, S
Mattioli, L
Oliva, L
Orsi, A
Pasqualetto, E
Pierre, P
Ruffato, E
Tagliavacca, L
Sitia, R
机构
[1] Univ Vita Salute San Raffaele, Dept Cell & Mol Biol, DIBIT, HSR, I-20132 Milan, Italy
[2] San Raffaele Sci Inst, DiBiT, Dept Biol & Technol, I-20132 Milan, Italy
[3] Univ Turin, Dept Vet Morphophysiol, Grugliasco, Italy
[4] Univ Brescia, Dept Biomed Sci & Biotecnol, Brescia, Italy
[5] Univ Mediterannee, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France
[6] Univ Genoa, Dept Expt Med, Genoa, Italy
关键词
apoptosis; myeloma; plasma cell; proteasome; unfolded protein response;
D O I
10.1038/sj.emboj.7601009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
After few days of intense immunoglobulin (Ig) secretion, most plasma cells undergo apoptosis, thus ending the humoral immune response. We asked whether intrinsic factors link plasma cell lifespan to Ig secretion. Here we show that in the late phases of plasmacytic differentiation, when antibody production becomes maximal, proteasomal activity decreases. The excessive load for the reduced proteolytic capacity correlates with accumulation of poly-ubiquitinated proteins, stabilization of endogenous proteasomal substrates (including Xbp1s, I kappa B alpha, and Bax), onset of apoptosis, and sensitization to proteasome inhibitors ( PI). These events can be reproduced by expressing Ig-mu chain in nonlymphoid cells. Our results suggest that a developmental program links plasma cell death to protein production, and help explaining the peculiar sensitivity of normal and malignant plasma cells to PI.
引用
收藏
页码:1104 / 1113
页数:10
相关论文
共 61 条
[1]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[2]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[3]  
Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO
[4]  
2-5
[5]   The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions [J].
Borner, C .
MOLECULAR IMMUNOLOGY, 2003, 39 (11) :615-647
[6]   Regulation of apoptosis by endoplasmic reticulum pathways [J].
Breckenridge, DG ;
Germain, M ;
Mathai, JP ;
Nguyen, M ;
Shore, GC .
ONCOGENE, 2003, 22 (53) :8608-8618
[7]   Building an antibody factory: a job for the unfolded protein response [J].
Brewer, JW ;
Hendershot, LM .
NATURE IMMUNOLOGY, 2005, 6 (01) :23-29
[8]   Regulatory mechanisms that determine the development and function of plasma cells [J].
Calame, KL ;
Lin, KI ;
Tunyaplin, C .
ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :205-230
[9]   IgM polymerization inhibits the Golgi-mediated processing of the mu-chain carboxy-terminal glycans [J].
Cals, MM ;
Guenzi, S ;
Carelli, S ;
Simmen, T ;
Sparvoli, A ;
Sitia, R .
MOLECULAR IMMUNOLOGY, 1996, 33 (01) :15-24
[10]   26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide [J].
Cascio, P ;
Hilton, C ;
Kisselev, AF ;
Rock, KL ;
Goldberg, AL .
EMBO JOURNAL, 2001, 20 (10) :2357-2366